ALNOV:EPA
Novacyt SA
€0.41
0.00%
(0.00) 1 天
11月6日, GMT+1 17:35:21 · EUR
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 ALNOV 生成关键数据洞见…
开盘价
€0.41
最高价
€0.41
最低价
€0.40
市值
2718.75万
平均成交量
18.77万
成交量
11.98万
52 周最高价
€1.04
52 周最低价
€0.29
每股收益
-€0.38
流通股数
7258.81万
员工人数
228
开盘价
€0.41
最高价
€0.41
最低价
€0.40
市值
2718.75万
平均成交量
18.77万
成交量
11.98万
52 周最高价
€1.04
52 周最低价
€0.29
每股收益
-€0.38
流通股数
7258.81万
员工人数
228
新闻报道
来自网络来源和新闻合作伙伴
TradingKey
·
2天前
标普500五个月几乎零涨幅：估值降至18.5倍，美股正在变便宜吗？
UA.NEWS
·
2天前
AI股票遭抛售后，纳斯达克上涨1.23%——BBC News
CryptoRank
·
1天前
glassnode：比特币与标普 500 指数的相关系数达 0.8，为 2020 年以来高位
Longbridge
·
1天前
【谋周记】闪电专挑暴雨天，暴跌之后怎么办（2026 年第45 周｜总第295 期）｜长桥证券
资料
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Novacyt SA简介